Abstract: A system can route calls based on a minimum expected delay, classification, and priority of the call. In some embodiments, when a call is received, the call is classified and prioritized within the classification. A minimum expected delay time is determined. Based on the minimum expected delay time, the classification, and the prioritization, the call is routed to a representative with instructions on how the call should be treated.

Abstract: The present invention relates to methods, devices and systems for associating consumable data with an assay consumable used in a biological assay. Provided are assay systems and associated consumables, wherein the assay system adjusts one or more steps of an assay protocol based on consumable data specific for that consumable. Various types of consumable data are described, as well as methods of using such data in the conduct of an assay by an assay system. The present invention also relates to consumables (e.g., kits and reagent containers), software, data deployable bundles, computer-readable media, loading carts, instruments, systems, and methods, for performing automated biological assays.

Abstract: The invention relates to imidazopyridinones, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. By activating TLRs, it should be possible to induce or stimulate immune cells to mount an immune response. In particular, the TLR7 has been implicated in viral infections (such as HCV or HBV), cancers and tumours, and T2 Helper cell (TH2) mediated diseases, and hence TLR7 agonists are potentially useful in the treatment of such diseases. We have now found a series of imidazopyridinones which are agonists of TLR7. According, there is provided a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is 3- to 8-membered saturated heterocyclic group wherein one ring member is O; and R2 is phenyl or pyridinyl, each optionally substituted by C1-C6alkyl.

Abstract: The invention relates to imidazopyridinones, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. By activating TLRs, it should be possible to induce or stimulate immune cells to mount an immune response. In particular, the TLR7 has been implicated in viral infections (such as HCV or HBV), cancers and tumours, and T2 Helper cell (TH2) mediated diseases, and hence TLR7 agonists are potentially useful in the treatment of such diseases. We have now found a series of imidazopyridinones which are agonists of TLR7. According, there is provided a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is 3- to 8-membered saturated heterocyclic group wherein one ring member is —O—; and R2 is phenyl or pyridinyl, each optionally substituted by C1-C6alkyl.

Abstract: The invention relates to imidazopyridinones, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. By activating TLRs, it should be possible to induce or stimulate immune cells to mount an immune response. In particular, the TLR7 has been implicated in viral infections (such as HCV or HBV), cancers and tumours, and T2 Helper cell (TH2) mediated diseases, and hence TLR7 agonists are potentially useful in the treatment of such diseases. We have now found a series of imidazopyridinones which are agonists of TLR7. According, there is provided a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is 3- to 8-membered saturated heterocyclic group wherein one ring member is —O—; and R2 is phenyl or pyridinyl, each optionally substituted by C1-C6alkyl.

Abstract: This invention relates to novel substituted 2-(3-aminophenoxymethyl)imidazolines which are useful for the treatment of diarrhea and useful as analgesics.

Abstract: The present invention relates to novel compounds for the prophylaxis and treatment of Inflammatory Bowel disease (IBD) via the administration of an effective amount in a suitable pharmaceutical dosage of a polymeric agent for releasing 5,5'-azobis-salicylic acid which comprises a non-degradable anionic exchange resin and the dianionic form of 5,5'-azobis-salicylic acid. The 5,5'-azobis-salicylic acid undergoes bacterial cleavage in the mammalian lower bowel to release 5-aminosalicylic acid.

Abstract: This invention provides 4-aroyl substituted phenoxy acetic acids and tetrazoles of the formula ##STR1## wherein R is a phenyl ring, a substituted phenyl ring, or naphthyl; R.sub.1 is --CH.sub.2 COOH or methyl tetrazole, and X.sub.1 and X.sub.2 are each a halogen or loweralkyl, or when taken together form with the two attached carbons a phenyl ring.These compounds are useful as antihypertensive agents, diuretics and uricosuric agents.

Abstract: This invention covers diacylated derivatives of .gamma.-glutamyl dopamine selected from the group consisting of ##STR1## where R is a C.sub.1 -C.sub.12 straight or branched chain alkyl radical, a phenyl ring or a substituted phenyl ring and R' is H or a C.sub.1 -C.sub.7 alkyl, and a pharmaceutically acceptable acid addition salt thereof.The compounds of this invention are useful to increase the renal blood flow by being administered to warm-blooded animals by clinically accepted routes of administration such as oral, parenteral, rectal and the like.

Abstract: This invention covers diacylated derivatives of .gamma.-glutamyl dopamine selected from the group consisting of ##STR1## where R is a C.sub.1 -C.sub.12 straight or branched chain alkyl radical, a phenyl ring or a substituted phenyl ring and R' is H or a C.sub.1 -C.sub.7 alkyl, and a pharmaceutically acceptable acid addition salt thereof.The compounds of this invention are useful to increase the renal blood flow by being administered to warm-blooded animals by clinically accepted routes of administration such as oral, parenteral, rectal and the like.